iRadimed reports Q4 EPS 44c vs 39c last year

Reports Q4 revenue $19.4M vs $17.5M last year. “We are proud to close out 2024 with another record-breaking quarter, marking our fourteenth consecutive quarter of revenue growth. Our strong performance was driven by sustained demand for our IV infusion pumps, robust gross and operating margins, and a growing order backlog that provides excellent momentum as we enter 2025. In light of our strong financial position and commitment to returning value to stockholders, we are pleased to announce an increase in our quarterly cash dividend from $0.15 to $0.17 per share. Additionally, construction of our new facility is progressing well, with completion set for mid-year. The facility will provide much-needed additional space to support our growth trajectory in the coming years. As we move forward, we remain committed to delivering innovative solutions and driving long-term value for our customers,” said Roger Susi, President and Chief Executive Officer of the Company.